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Triple-negative breast cancers (TNBCs) are a heterogeneous set of cancers that are defined by the absence of hormone
receptor expression and HER2 amplification. Here, we found that inducible IκB kinase–related (IKK-related) kinase IKBKE
expression and JAK/STAT pathway activation compose a cytokine signaling network in the immune-activated subset of
TNBC. We found that treatment of cultured IKBKE-driven breast cancer cells with CYT387, a potent inhibitor of TBK1/
IKBKE and JAK signaling, impairs proliferation, while inhibition of JAK alone does not. CYT387 treatment inhibited
activation of both NF-κB and STAT and disrupted expression of the protumorigenic cytokines CCL5 and IL-6 in these
IKBKE-driven breast cancer cells. Moreover, in 3D culture models, the addition of CCL5 and IL-6 to the media not only
promoted tumor spheroid dispersal but also stimulated proliferation and migration of endothelial cells. Interruption of
cytokine signaling by CYT387 in vivo impaired the growth of an IKBKE-driven TNBC cell line and patient-derived xenografts
(PDXs). A combination of CYT387 therapy with a MEK inhibitor was particularly effective, abrogating tumor growth
and angiogenesis in an aggressive PDX model of TNBC. Together, these findings reveal that IKBKE-associated cytokine
signaling promotes tumorigenicity of immune-driven TNBC and identify a potential therapeutic strategy using clinically
available compounds.

Introduction

Advances in targeted therapy for patients with breast cancers
that express estrogen/progesterone receptors and/or HER2 have
improved patient outcomes and survival. Limited treatment options
exist, however, for the 15% to 20% of patients with triple-negative
breast cancers (TNBCs). Although TNBCs may respond to anthracycline-based chemotherapy or cisplatin, tumors frequently relapse,
resulting in decreased disease-free and overall survival compared
with other breast cancer subtypes (1).
The diversity of somatic mutations, gene amplifications, and
deletions observed in TNBC has hampered efforts to elucidate
a common drug target in this breast cancer subtype (2). Recent
evidence suggests that a significant fraction of TNBCs exhibit
immune cell infiltration, with features of stem cells and epithelial-
mesenchymal transition (3–5). Indeed, a refined classification of
TNBC based on gene expression profiling recently identified an
immunomodulatory (IM) subtype that corresponds with this category of tumors (6). However, the specific genetic drivers of this
and other TNBC subtypes remain poorly defined.
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consultant for Novartis.
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The IκB kinase–related (IKK-related) kinases TANK-binding
kinase 1 (TBK1) and IĸB kinase ε (IKBKE, also known as IKKε)
represent an emerging link between inflammation and cancer (7).
In response to pathogen exposure, induction of IKBKE reinforces
TBK1 signaling and promotes sustained activation of the type 1
interferon pathway (8–11). Furthermore, IKBKE directly phosphorylates and activates specific STAT transcription factors (12, 13),
and cytokines produced by TBK1/IKBKE can engage downstream
JAK/STAT signaling in an autocrine or paracrine fashion (14).
IKBKE is also aberrantly expressed and/or amplified in
approximately 30% of breast carcinomas (15–17), in which it
induces survival signaling associated with NF-κB pathway activation. IKBKE activation facilitates cell transformation, whereas
suppression of IKBKE in breast cancer cell lines that harbor IKBKE
amplification or overexpression results in cell death (16). IKBKE
phosphorylates CYLD and TRAF2 in breast cancer cells, which
induces NF-κB activation and contributes to cell transformation
(18, 19). However, a comprehensive understanding of how IKBKE
promotes tumorigenicity is lacking, and the therapeutic efficacy of
targeting IKBKE signaling in vivo has yet to be defined.
Activation of NF-κB and JAK/STAT signaling has been strongly
implicated in the pathogenesis of certain TNBCs and closely related
basal-like breast cancers (20–24). Markers of JAK/STAT pathway
activation are particularly enriched in the IM TNBC gene expresjci.org   Volume 124   Number 12   December 2014
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Table 1. IKBKE copy number in ZR-751– and IKBKE-expressing
TNBC cell lines from the Broad/Novartis Cell Line Encyclopedia
Cell line
ZR751
MDA-MB-231
MDA-MB-468
HCC70
HCC1143
HCC1187

IKBKE CN (log2 [CN/2])
1.23
0.12
0.36
0.47
0.49
0.53

CN, copy number.

sion subtype (6). Here, we report that, in addition to its genomic
amplification in luminal breast tumors, IKBKE is aberrantly overexpressed in TNBC and coordinately activates NF-κB, STAT, and
cytokine signaling in this subset of cancers. Furthermore, we identify combined TBK1/IKBKE, JAK, and MEK inhibition as a novel
potent therapeutic strategy for this class of tumors.

Results

Identification of an IKBKE-driven TNBC subtype. IKBKE is amplified
in approximately 30% of human breast tumors, and luminal breast
cancer cell lines that harbor IKBKE copy gain are dependent upon
its expression (16). IKBKE overexpression has also been observed
in breast cell lines and cancers without IKBKE amplification, such
as the TNBC cell lines, MDA-MB-231 and MDA-MB-468 (17). To
gain further insight into IKBKE regulation and function in breast
cancer, we analyzed gene expression data from primary breast
cancers profiled in the The Cancer Genome Atlas (TCGA) data set
(2). Whereas IKBKE expression was linked with IKBKE amplification in luminal tumors, a substantial additional fraction of breast
cancers overexpressed IKBKE in the absence of gene amplification (Figure 1A). Since IKBKE is also induced by multiple different cytokines (25), we examined correlation between the levels of
several different cytokine gene expression signatures and IKBKE
mRNA expression across these samples (26, 27). Among these signatures, IL-1 induction correlated most strongly with high IKBKE
levels in a subtype of TNBC, followed by TNFA (P < 0.001 for
both, normalized mutual information (NMI) statistic) (Figure 1A
and Supplemental Figure 1, A and B). Hierarchical clustering with
previously reported gene expression subtypes (6) and B lymphocyte markers (28) further revealed that IKBKE expression and IL-1
activation most closely associated with the IM subtype of TNBC
and with lymphocytic infiltration (P < 0.001 and P < 0.02, respectively, NMI statistic) (Supplemental Figure 1C). IKBKE mRNA levels correlated with mutant TP53 status across all TCGA tumors,
but this did not reach statistical significance within the TNBC subset (Supplemental Figure 2A). Response to neoadjuvant cisplatin
therapy failed to correlate with IKBKE expression status in another
cohort of patients with TNBC (Supplemental Figure 2A).
To explore this observation further, we next identified cell
lines that express elevated IKBKE levels using gene expression
data from the Broad/Novartis Cell Line Encyclopedia (29). Similar
to ZR751, a luminal breast cancer cell line that harbors IKBKE copy
number gain (16), and in contrast to HER2+ BT474 cells or non5412
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transformed MCF-10A cells, we identified several TNBC cell lines
that expressed high levels of IKBKE protein (Figure 1B). Whereas
ZR751 cells exhibited copy number gain at the IKBKE locus as
expected, multiple IKBKE-expressing TNBC cell lines failed to
show evidence of genomic IKBKE amplification (Table 1). These
findings recapitulated what we had observed in primary tumors
and confirmed that IKBKE is not only amplified in luminal breast
cancers but also aberrantly overexpressed in a subset of TNBC.
IKBKE-amplified ZR751 cells depend on IKBKE expression
for their proliferation and survival (16). Using 2 independent
IKBKE-specific shRNAs, we found that TNBC MDA-MB-468 cells
were at least as sensitive to suppression of IKBKE as ZR751 cells
(Figure 1C). Indeed, whereas specific depletion of IKBKE failed
to affect the proliferation of nontransformed MCF10A cells, we
confirmed that suppression of IKBKE expression inhibited the
proliferation of multiple IKBKE-amplified (ZR751 and MCF7) and
IKBKE-overexpressing TNBC cell lines (MDA-MB-231 and MDAMB-468) (Figure 1D). These findings revealed that IKBKE is not
only overexpressed but also contributes to the proliferation and
survival of this subset of TNBC.
IKBKE expression in TNBC is associated with STAT3 activation
and cytokine production. IKBKE promotes NF-κB (7) and STAT signaling (12, 13) both directly and indirectly via autocrine cytokine
production (14). Indeed, we confirmed that IKBKE overexpression
in HEK-293T (293T) cells not only induced NF-κB pathway activation, as measured by S933 phosphorylated NF-κB p105 levels, but
also STAT3 activation, as reflected by increased Y705 phosphorylated STAT3 (pSTAT3) levels (Figure 2A). Activation of these signaling pathways by IKBKE was associated with induction of CCL5
expression in a kinase-dependent manner (Figure 2B). When we
measured IKBKE levels and activated STAT3 (as measured by Y705
pSTAT3 levels) across breast cancer cell lines, we observed correlation preferentially in TNBC cell lines (Figure 2C). These findings
suggested that engagement of IKBKE signaling in TNBC occurred
within the context of a broader cytokine signaling network. Since
elevated IKBKE expression in TNBC tumors correlated with IL-1
and other markers of inflammation (Figure 1A and Supplemental
Figures 1, A–C), we assessed the role of IL-1β in engaging IKBKE
signaling in this context. Indeed, treatment of multiple TNBC cell
lines with IL-1β led to a substantial further increase in IKBKE protein levels (Figure 2D) and enhanced the secretion of CCL5 (Figure
2E). Depletion of IKBKE alone in MDA-MB-468 cells failed to prevent IL-1β–induced CCL5 production but modestly reduced IL-6
levels (Supplemental Figure 3, A and B). These observations support the view that functional redundancy exists between multiple
components of this network, including TBK1, which together with
IKBKE promotes CCL5 and IL-6 production (30).
Sensitivity of IKBKE-driven TNBC cells to CYT387 treatment.
We next compared the effects of selective inhibition of JAK/STAT
signaling on TNBC cell proliferation and survival by treatment
with the JAK inhibitor ruxolitinib (31) or the multitargeted JAK/
TBK1/IKBKE inhibitor CYT387 (30, 32, 33). Treatment of MDAMB-468 cells with ruxolitinib or CYT387 over a range of doses
inhibited STAT3 phosphorylation (Figure 3A). Despite comparable
inhibition of JAK signaling, treatment of these cells with CYT387
but not ruxolitinib impaired the viability of multiple different
TNBC cell lines (Figure 3, B and C).
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Figure 1. IKBKE overexpression defines a subset of TNBCs. (A) IKBKE amplification and mRNA expression in the TCGA breast cancer data set, compared
with IL-1 signature enrichment by single-sample gene set enrichment analysis (ssGSEA). Light purple represents basal but progesterone receptor–positive
tumors. Black lines indicate IKBKE amplification on 1q32, red indicates high expression, and blue indicates low expression. (B) Immunoblot of IKBKE and
β-actin levels across a panel of TNBC cell lines compared with BT474 (HER2+), ZR-751 (luminal, IKBKE-amplified), and MCF-10A (basal-like, nontransformed) cells. (C) Relative cell viability by CellTiter-Glo (CTG) Luminescent Cell Viability Assay on day 3 or day 10 following expression of 2 different IKBKE
shRNAs compared with shGFP control in ZR-751 or MDA-MB-468 cells. Values represent mean and SEM of triplicate samples. (D) Crystal violet–stained
cells and immunoblots of IKBKE and β-actin levels from parallel wells following control shGFP expression or that of 2 different IKBKE-specific shRNAs in
the indicated cell lines.

We further examined the effects of CYT387 treatment on
MDA-MB-468 cells in a 3D culture tumor spheroid dispersal assay
that captures features of the tumor microenvironment and also
models aspects of the epithelial-mesenchymal transition (34). EGF-
induced proliferation of MDA-MB-468 breast cancer cells in this
assay was completely suppressed by CYT387 treatment at concentrations as low as 800 nM (Supplemental Figure 4A). We also cultured several other TNBC cell lines in 3D suspension together with

IL-1β and found that CYT387 treatment inhibited proliferation and
caused cells to aggregate (Supplemental Figure 4B). These findings
demonstrate that CYT387 treatment uniquely impairs not only cell
viability in 2D culture but also growth factor– and cytokine-driven
TNBC cell proliferation and dispersal in 3D culture.
Next, we treated a panel of 15 breast cancer cell lines with CYT387
over a range of concentrations and found that TNBCs that exhibited
high levels of IKBKE and pSTAT3 exhibited the greatest sensitivity,
jci.org   Volume 124   Number 12   December 2014
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Figure 2. IKBKE promotes inflammatory signaling and is induced by IL-1 in TNBC cells. (A) Immunoblot of IKBKE, S933 p-p105, total p105, Y705 pSTAT3,
total STAT3, and β-actin in 293T cells transiently transfected with IKBKE or a control EGFP-expressing vector. (B) CCL5 mRNA expression in 293T cells following transient transfection with EGFP, IKBKE-WT, and IKBKE-K38A. Values were normalized to EGFP and represent the mean and SEM of triplicate samples.
(C) Immunoblot of IKBKE, Y705 pSTAT3, total STAT3, and β-actin in a panel of 15 breast cancer cell lines. (D) Immunoblot of IKBKE and β-actin in a panel of
TNBC cell lines with or without exogenous IL-1β (25 ng/ml) for 24 hours. (E) CCL5 levels in the media measured by ELISA following IL-1β (25 ng/ml) treatment
of IKBKE-expressing TNBC cell lines for 24 hours. Values represent mean and SD of duplicate samples.

suggestive of a relationship between IKBKE activation and CYT387
treatment (Figure 2A and Figure 3D). Corroborating these findings, immortalized human mammary epithelial cells that expressed
IKBKE (16) were more sensitive to CYT387 treatment than isogenic
cells expressing a control vector, whereas ruxolitinib exposure had no
effect on these cells (Figure 3E). Taken together, these observations
reveal that CYT387, unlike ruxolitinib, selectively impairs TNBC cell
viability in a manner that correlates with IKBKE expression.
Activity of CYT387 in TNBC directly involves inhibition of IKBKE
signaling. To assess the direct consequences of CYT387 treatment
on IKBKE activity, beyond CYT387’s TBK1-specific effects (30),
we transiently transfected 293T cells with IKBKE and measured
downstream signaling pathways in the absence or presence of this
inhibitor. Compared with expression of an EGFP control vector,
exogenous overexpression of IKBKE primarily activated multiple STAT family members as well as p38α, and these effects were
inhibited by CYT387 treatment (Supplemental Figure 5A). Both
CYT387 and ruxolitinib inhibited IKBKE-induced Y705 pSTAT3
levels, consistent with suppression of autocrine cytokine signaling through JAK kinases (Figure 4A). IKBKE-induced pSTAT5 was
also inhibited by CYT387 and ruxolitinib treatment (Supplemental
Figure 5B). In contrast, when we measured phosphorylated p38α
levels following treatment of IKBKE-expressing 293T cells or
5414
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MDA-MB-468 cells with CYT387 or ruxolitinib, we were unable to
observe significant changes in this marker, which suggests a lack of
a direct relationship between p38α and IKBKE or JAK activity (Supplemental Figure 5, C and D).
We next examined the effects of CYT387 or ruxolitinib treatment on IKBKE-induced NF-κB signaling. IKBKE-induced p105
phosphorylation in 293T cells was inhibited by CYT387 treatment
but not ruxolitinib treatment (Figure 4B). We confirmed that p105
was phosphorylated at a baseline low level in both MDA-MB-468
cells and MDA-MB231 cells and that CYT387 treatment also selectively inhibited phosphorylated p105 (p-p105) levels in these TNBC
cell lines compared with ruxolitinib treatment (Figure 4C). IL-1β
stimulation further induced S933 p105 phosphorylation in MDAMB-468 cells, which was also selectively inhibited by CYT387
treatment, in contrast to ruxolitinib treatment, and resulted in
p105 stabilization (Figure 4D). CYT387 treatment also suppressed
IKBKE expression in MDA-MB-468 cells, in contrast to that of
IKKβ or IKKα (Figure 4E). We further confirmed that CYT387
treatment inhibited p-p105, pSTAT3, and IKBKE levels in multiple
other IKBKE-driven TNBC cell lines (Supplemental Figure 5, E and
F). Thus, in contrast to ruxolitinib treatment, CYT387 treatment
inhibits multiple components of the inflammatory signaling network that sustain proliferation and survival of this TNBC subtype.
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Figure 3. Sensitivity of IKBKE-expressing TNBC cells to CYT387. (A) Immunoblot of Y705 pSTAT3, total STAT3, and β-actin in MDA-MB-468 cells following
ruxolitinib or CYT387 treatment at the indicated concentrations for 1 hour. (B) Phase-contrast microscopy (original magnification, ×10) of crystal violet–
stained MDA-MB-468 or MDA-MB-231 cells treated with DMSO, 5 μM ruxolitinib, or 5 μM CYT387 for 3 days. (C) Relative viability by CTG assay of multiple
IKBKE-driven TNBC cell lines following CYT387 or ruxolitinib treatment for 5 days, normalized to control DMSO treatment. Values represent mean and
SEM of triplicate samples. (D) IC50 values for CYT387 treatment across a panel of 15 breast cancer cell lines treated with serial dilutions of CYT387 or DMSO
as a control. Cell viability was measured after 5 days using CTG and normalized to values obtained from DMSO-treated cells. TNBC cell lines are indicated
in purple. (E) Relative cell viability of immortalized human mammary epithelial cells (HMLE) isogenic for IKBKE expression (myristolated-Flag-IKBKE or
vector control) treated with 5 μM CYT387 or ruxolitinib for 5 days, normalized to control DMSO treatment. Mean and SEM of triplicate samples shown.
**P < 0.001 by t test.

To examine more directly the role of IKBKE inhibition by
CYT387 in TNBC proliferation and survival, we used a CYT387-
resistant allele, IKBKE-Y88C, identified by homology to JAK2 (30,
35). We stably expressed the IKBKE-Y88C allele in MDA-MB-468
cells and selected the cells in the presence of 2.5 μM CYT387 for
3 weeks. We confirmed that the cells that emerged markedly overexpressed IKBKE-Y88C compared with control EGFP-expressing
MDA-MB-468 cells (Figure 4F). CYT387 treatment of MDA-MB468-IKBKE-Y88C cells failed to suppress IKBKE expression or
baseline levels of p-p105, consistent with downstream resistance
to this activity (Figure 4F). Treatment of MDA-MB468-IKBKEY88C cells with CYT387 resulted in enhanced proliferation and
survival in vitro compared with control cells that expressed EGFP
(Figure 4G). These observations confirm that inhibition of IKBKE
by CYT387 directly contributes to its antiproliferative activity in
IKBKE-driven TNBC cells.

CYT387 treatment disrupts IKBKE-induced protumorigenic
cytokine expression. Given the unique ability of CYT387 to target
this signaling network, we next tested its impact on autocrine
cytokine expression. We collected media from 293T cells 24
hours following transient transfection with EGFP or IKBKE and
analyzed levels of 36 different cytokines and chemokines using a
cytokine antibody array. Enforced expression of IKBKE potently
induced CCL5 levels in the media, consistent with what was
observed at the mRNA level (Figure 2B), and was the dominant
secreted factor at this time point (Figure 5A). IKBKE-dependent
CCL5 production was completely abrogated by CYT387 treatment
but was negligibly affected by ruxolitinib treatment (Figure 5A).
To confirm these observations, we used ELISA to measure CCL5
levels in addition to those of IL-6 and found that IKBKE-induced
CCL5 and IL-6 were strongly inhibited by CYT387 treatment,
whereas they were only partially suppressed by ruxolitinib treatjci.org   Volume 124   Number 12   December 2014
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Figure 4. Inhibition of JAK and
IKBKE signaling by CYT387. (A)
Immunoblot of IKBKE, Y705
pSTAT3, total STAT3, and β-actin
following transient transfection
of 293T cells with IKBKE and
treatment with 5 μM ruxolitinib
or CYT387. Lysates were obtained
24 hours after transfection and
12-hour inhibitor treatment. (B)
Immunoblot of S933 p-p105,
p105, and β-actin following
IKBKE overexpression in 293T
cells and 5 μM ruxolitinib or
CYT387 treatment. (C) Immunoblot of S933 p-p105, p105, and
β-actin in MDA-MB-468 or MDAMB-231 cells with endogenous
IKBKE overexpression following
1-hour treatment with 5 μM
ruxolitinib or CYT387. (D) Immunoblot of S933 p-p105, p105,
p50, and β-actin in MDA-MB-468
cells pretreated with DMSO, 5
μM ruxolitinib, or 5 μM CYT387
for 1 hour and stimulated with
IL-1β for the indicated times. (E)
Immunoblot of IKBKE, IKKα, and
IKKβ in MDA-MB-468 cells 24
hours following treatment with
DMSO, ruxolitinib, or CYT387 at
the indicated concentrations,
each compared with β-actin as a
loading control. (F) MDA-MB-468
cells were stably infected with
IKBKE-Y88C and selected in
2.5 μM CYT387 for 3 weeks.
Immunoblot shows IKBKE,
S933 p-p105, p105, and β-actin
in these cells compared with
control EGFP-expressing MDAMB-468 cells following DMSO
or CYT387 treatment. (G) Cell
viability measured by CTG on day
3 or day 10 following treatment
of MDA-MB-468-EGFP or IKBKEY88C cells with DMSO or CYT387.
Values were normalized to DMSO
as a control and represent mean
and SEM of triplicate samples.
Crystal violet–stained wells are
shown below.
5416
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ment (Figure 5B). These findings reveal that CYT387 treatment
not only inhibits both STAT3- and IKBKE-induced p105 phosphorylation but also uniquely ablates the production of CCL5 and IL-6
following IKBKE overexpression.
We next assessed whether CYT387 inhibition of this network
also impaired the production of CCL5 and IL-6 in TNBC cell lines.
Treatment of MDA-MB468, MDA-MB231, HCC1187, or HCC70
cells with CYT387 in general prevented IL-1β–induced CCL5 and
IL-6 (Figure 5C and Supplemental Figure 6A). To examine the consequences downstream of CCL5 and IL-6 production on TNBC
proliferation, we first tested whether the addition of exogenous
CCL5 and/or IL-6 rescued the viability of CYT387-treated MDAMB-468 cells in 2D culture. We observed a modest but significant
rescue following treatment with either cytokine or the combination of both (P < 0.001) (Supplemental Figure 6B). In contrast,
in 3D culture, CCL5 and IL-6 not only promoted MDA-MB-468
cell migration and proliferation as effectively as EGF but they also
completely rescued the inhibition of spheroid dispersal by CYT387
(Figure 5D). Taken together, these observations demonstrate that
IKBKE-driven CCL5 and IL-6 directly contribute to TNBC migration and proliferation of tumor spheroids, which is disrupted by
CYT387 treatment.
TBK1/IKBKE-regulated cytokines also influence the tumor
microenvironment and angiogenesis in particular (36). We
therefore used another 3D device optimized to study the effects
of IKBKE-induced CCL5/IL-6 on HUVEC behavior in collagen
(Figure 5E and ref. 37). First, we overexpressed IKBKE-WT in
293T cells, seeded them in the opposing channel, and found
that expression of IKBKE-WT induced HUVEC migration, in
contrast to EGFP and IKBKE-KD controls (Supplemental Figure 6C). Next, we directly supplemented media with CCL5 and
IL-6 and observed that these cytokines induced both endothelial cell migration and proliferation (Figure 5F and Supplemental Figure 6D). Because of the proliferation, we tested whether
cotreatment of CCL5/IL-6 with the MEK inhibitor GSK1120212
prevented this phenotype, and indeed HUVEC migration was
abrogated (Figure 5F). Taken together, IKBKE-regulated CCL5
and IL-6 induce the proliferation and migration of TNBC and
endothelial cells, consistent with both autocrine and paracrine
tumor-promoting activities.
Inhibition of IKBKE by CYT387 contributes to its therapeutic
potential in vivo. To determine efficacy of CYT387-based treatment in vivo, we first tested its therapeutic impact on MDAMB-468 tumor xenograft growth and the relationship with
IKBKE inhibition. After tumors were established in immunodeficient mice at an average volume of 50 mm3, CYT387 was
administered via daily oral gavage at a dose of 100 mg/kg (33).
Compared with a vehicle control, CYT387 treatment at this
dose effectively inhibited pSTAT3 expression in tumors (Figure
6A) and strongly suppressed tumor progression (Figure 6B).
In consonance with our observations in vitro, CYT387 treatment did not affect the growth of MDA-MB-468 IKBKE-Y88C
xenografts (Figure 6B).
We next explored single-agent CYT387 activity in a system
that more closely recapitulates human tumor physiology using
patient-derived breast cancer xenografts (PDXs). First, we examined therapy in two different Washington University human-
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in-mouse (WHIM) lines (WHIM4 and WHIM21) that were
derived from patients with TNBC that overexpressed IKBKE (ref.
38 and Supplemental Figure 7A). Similar to what we observed following treatment of MDA-MB-468 xenografts, CYT387 treatment
impaired the growth of established PDX WHIM4 tumors and
WHIM21 tumors, the latter a particularly aggressive model that
recurred rapidly following neoadjuvant doxorubicin/cyclophosphamide and paclitaxel chemotherapy (ref. 38 and Figure 6C).
Inhibition of WHIM21 PDX growth was associated with disruption
of human IKBKE, CCL5, and IL6 expression, confirming effective interruption of autocrine cytokine signaling in these tumors
(Figure 6D). Taken together, these findings reveal that inhibition
of TBK1/IKBKE and JAK signaling by CYT387 suppresses protumorigenic cytokine expression and exhibits therapeutic potential
for IKBKE-driven TNBC.
Synergistic response to combined CYT387 and GSK1120212
therapy. MEK inhibition in TNBC not only results in feedback
activation of receptor tyrosine kinases but also induces cytokine
expression, suggesting the possibility of synergy with CYT387
treatment (39). In addition the requirement of MEK signaling for
CCL5/IL-6–induced proliferation/migration of endothelial cells
(Figure 5F) indicated the potential for dual impairment of angiogenesis. We therefore treated established WHIM21 tumors with
CYT387 (50 mg/kg/d), GSK1120212 (2.5 mg/kg/d), or combination CYT387/GSK1120212 therapy by oral gavage. The drug combination was well tolerated, and, in contrast to either of the single
agents, markedly impaired tumor progression (Figure 7A). Indeed,
several of the largest established tumors also showed evidence of
tumor regression (Supplemental Figure 7B). We confirmed that
dual CYT387 and GSK1120212 treatment effectively inhibited
both phosphorylated ERK (pERK) and pSTAT3 levels in treated
WHIM21 tumors, confirming suppression of multiple pathways by
this drug combination in vivo (Figure 7B).
To assess the dose-dependent effect of this impressive activity, we further reduced CYT387 to 10 mg/kg daily and compared
results with vehicle or high-dose ruxolitinib treatment (Supplemental Figure 6A). Treatment of WHIM21 tumors with just a
2-week course of low-dose CYT387/GSK1120212 led to marked
and persistent inhibition of tumor progression at 4 weeks, in contrast to continuous vehicle or ruxolitinib treatment at 100 mg/kg
daily over the entire time period (Supplemental Figure 8A).
Response to this low-dose CYT387 regimen was also examined
in WHIM12 PDX tumors, derived from a patient with TNBC with
low IKBKE levels (Supplemental Figure 6A). WHIM12 tumors
responded to CYT387/GSK1120212 treatment though not as
dramatically as WHIM21 tumors, with some tumors progressing
despite therapy (Supplemental Figure 8B).
In addition to their small size, we also noted that WHIM21
tumors treated with the combination of CYT387 and GSK
1120212 appeared particularly pale compared with vehicle- or
single-agent–treated tumors (Figure 7C and Supplemental Figure 7C). We therefore performed a detailed histologic examination of treated tumors, including measures of angiogenesis.
Whereas single-agent treatment with GSK1120212 showed
preferential impairment of proliferation, as measured by Ki67
staining, and CYT387 modestly reduced microvascular density,
the combination resulted in a striking inhibition of angiogenejci.org   Volume 124   Number 12   December 2014
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Figure 5. Inhibition of this network by CYT387 suppresses protumorigenic
cytokines. (A) Cytokine antibody array incubated with media from 293T cells
transfected with EGFP or IKBKE for 24 hours and pretreated with DMSO,
5 μM CYT387, or 5 μM ruxolitinib for 12 hours. Circles represent the location of
CCL5, the predominant cytokine induced by IKBKE and inhibited by CYT387,
compared with ruxolitinib. (B) ELISA measurement of CCL5 or IL-6 levels in
293T cells expressing IKBKE and treated with DMSO, 5 μM ruxolitinib, or
5 μM CYT387. Mean and SD of duplicate samples shown. (C) ELISA measuring
CCL5 or IL-6 levels in MDA-MB-468 cells or MDA-MB-231 cells stimulated with
IL-1β for 24 hours following pretreatment with DMSO or 5 μM CYT387 for
1 hour. Mean and SD of duplicate samples shown. (D) Phase-contrast images
(original magnification, ×20) of MDA-MB-468 spheroids in microfluidic 3D
culture at baseline and 24 and 48 hours following addition of CCL5/IL-6, EGF,
or the combination of both, together with DMSO as a control (left). Treatment
with 1 μM CYT387 inhibited EGF-induced MDA-MB-468 spheroid dispersal,
but this was rescued by the addition of CCL5 and IL-6 (right). (E) Schematic of
angiogenesis microfluidic device. HUVECs were seeded in central channel and
subjected to cytokine/chemokine diffusion as indicated. (F) Compared with
control media, diffusion of CCL5/IL-6–attracted HUVECs into collagen (original
magnification, ×20) over the course of 24 hours. Cotreatment with the MEK
inhibitor (MEKi), GSK1120212, at 10 nM strongly inhibited this effect. Mean
and SD of cell migration per number from 3 independent devices shown.
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Figure 6. CYT387 inhibits IKBKE signaling and tumor progression in vivo. (A) MDA-MB-468 cells were implanted subcutaneously in nude mice, and
following the development of established xenograft tumors, vehicle or CYT387 100 mg/kg was administered daily by oral gavage. Levels of pSTAT3 were
measured by immunohistochemistry following short-term treatment. HE, hematoxylin eosin stain. Scale bar: 25 μM. (B) Mean tumor volume ± SEM
following vehicle (n = 4) or CYT387 (n = 5) treatment over time in MDA-MB-468 or MDA-MB-468 IKBKE-Y88C xenografts. (C) Mean tumor volume ± SEM
following vehicle (n = 5) or CYT387 100 mg/kg/d (n = 5) treatment over 14 days in WHIM4 and WHIM21 primary human tumor xenografts. (D) Relative
mRNA levels of human IKBKE, CCL5, and IL6 in WHIM21 tumors following short-term vehicle or CYT387 treatment. Values represent mean and SEM of
triplicate samples from 2 different animals.

sis and profound tumor necrosis (Figure 7D and Supplemental
Figure 9). Thus, antitumor activity of this drug combination was
not only direct but was also related to the synergistic effects of
cytokine and MEK inhibition on angiogenesis. Taken together,
combined CYT387 and GSK1120212 treatment impairs tumor
progression and angiogenesis and represents a promising novel
therapy for this IKBKE-driven subtype of TNBC.

Discussion

TNBC has been defined by the lack of ER and HER2 expression,
but several lines of evidence suggest that TNBCs are a heterogeneous set of breast cancers (40). Here, we identify a specific
TNBC subset characterized by aberrant expression of the IKK-
related kinase IKBKE and production of protumorigenic cytokines CCL5 and IL-6. These tumors show substantial overlap with
the IM subtype of TNBC, recently identified by gene expression
profiling studies (6). In contrast to luminal tumors, which exhibit
IKBKE amplification (16), these triple-negative tumors exhibit
inducible IKBKE expression associated with markers of IL-1 sig-

naling and lymphocytic infiltration. Despite engagement of the
JAK/STAT pathway (24), treatment with the potent and selective JAK1/2 inhibitor ruxolitinib was insufficient to impair viability of these TNBCs. Instead, another clinical stage JAK inhibitor,
CYT387, impaired the proliferation of TNBC cells in vitro and
prevented tumor spheroid dispersal in 3D culture. The efficacy
of CYT387 was directly related to its additional ability to inhibit
IKBKE activity and the production of protumorigenic cytokines,
since exogenous CCL5 and/or IL-6, or expression of a CYT387
inhibitor–resistant allele of IKBKE, rescued these effects. These
observations suggest a promising therapeutic option for a subset
of patients with IKBKE-driven TNBC.
Integrative genomic studies identified a key role for aberrant
IKBKE activation in breast cancer by virtue of its amplification in a
subset of luminal tumors (16). IKBKE is unique among IKK family
members in that cytokines such as IL-1 that promote NF-κB signaling (25) and STAT3 activation (41), which induces its expression.
The finding that high level IKBKE expression in the IM subtype
of TNBC was linked more closely to engagement of inflammatory
jci.org   Volume 124   Number 12   December 2014
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Figure 7. Activity of CYT387/GSK1120212 combination therapy in an aggressive TNBC PDX model. (A) Spider plot depicting the percentage of
change in tumor volume of individual WHIM21 tumors treated with vehicle (n = 8), 50 mg/kg/d CYT387 (n = 3), 2.5 mg/kg/d GSK1120212 (n = 4), or
CYT387 and GSK1120212 (n = 9). (B) Immunoblot of pERK1/2, ERK1/2, Y705 pSTAT3, STAT3, and β-actin levels in tumors from vehicle-treated mice
or 2 different mice treated short term with vehicle, CYT387 (CYT), GSK1120212 (GSK), or the combination of CYT387 and GSK1120212 (CYT+GSK). (C)
Representative WHIM21 tumors dissected from vehicle or CYT387/GSK1120212-treated mice after 30 days. (D) Quantification of proliferation (Ki67),
microvascular density (CD31 or ERG), and tumor necrosis of tumors dissected after 30 days of the indicated treatments. Data represent mean and
SD values quantified from >5 distinct tumor regions from vehicle- (n = 3), CYT387- (n = 2), GSK1120212- (n = 2), or CYT387/GSK1120212-treated (n = 2)
mice. COMBO, CYT387 and GSK1120212.

signaling than to genomic amplification reveals an alternative
route to oncogenic IKBKE activation in TNBC, similar to what was
recently described in a subset of lung cancers (41). While IKBKE
drives the expression of these cytokines, engagement of other
kinases, including TBK1, likely also contributes to inflammatory
signaling in this subtype, since multitargeted IKBKE, TBK1, and
JAK signaling was required to disrupt this circuit. Since other non-
TNBC breast cancers also overexpress IKBKE and also activate
TBK1 signaling (42), such tumors could also respond to TBK1/
IKBKE and JAK inhibition by CYT387.
Our studies also identified key downstream roles for CCL5
and IL-6 as IKBKE-driven mediators of cell proliferation, survival, and migration of breast cancer cells. CCL5 induces plei5420
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otropic effects on NF-κB target gene expression (43) and AKT
activation (44, 45) and, like IL-6, directly engages JAK/STAT
signaling (46). Thus, NF-κB and STAT3 not only induce the
production of CCL5 and IL-6, but they also engage these same
pathways and activate IKBKE expression itself (41) to amplify
and sustain their expression as components of an inflammatory
circuit (30). Induction of CCL5, which promotes cell survival
and metastasis, has also been observed in breast cancer following coculture with mesenchymal stem cells (44). These findings
suggest that paracrine effects due to interactions within tumor
microenvironment likely facilitate engagement of this signaling
pathway. Since we observed an important role of IL-1 signaling in
driving this phenotype, it will be interesting to examine whether
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the source of this cytokine in primary breast tumors is derived
from mesenchymal stem cells, tumor-associated macrophages,
and/or other cell types in the tumor microenvironment.
IKBKE-induced CCL5 and IL-6 expression also stimulated
HUVEC proliferation, consistent with a previous report showing
that conditioned media from TBK1-transfected cells promotes
vascular cell proliferation (36). Our findings confirm and extend
these data, revealing a particular role for MEK signaling downstream of these cytokines in mediating endothelial cell proliferation and identifying synergistic inhibition of angiogenesis by
CYT387 and MEK inhibition in vivo. Cytokines such as CCL5
may also promote TNBC growth by influencing the local immune
microenvironment, since it also influences recruitment of myeloid-derived suppressor cells to tumors and promotes local immunosuppression (47). Analysis of such cells is challenging in PDX
models, given the altered immune background of nude mice, but
will be important to evaluate in future studies. Thus, CYT387
therapy may be particularly effective in vivo due to the additional
disruption of these tumor-stromal interactions.
Clinical trials of selective JAK1/2 inhibitors such as ruxolitinib have been initiated in patients with breast cancer (48).
While JAK/STAT signaling is clearly active in this subset of
TNBC, our data suggest that JAK inhibition alone may not be
sufficient to disrupt this cytokine circuit. Furthermore, although
certain markers, such as CD44+CD24– positivity or the IM gene
expression profile, have been associated with this particular
TNBC phenotype (6, 24, 49), the underlying driver of cytokine
activation in these cancers has remained elusive. The identification of IKBKE as a key driver of this cytokine signaling network
provides not only provides an additional marker of this emerging TNBC subtype but also a discrete molecular target. It is also
becoming increasingly apparent that targeting the source of
these upstream cytokines represents an equally important strategy to target TNBC growth compared with JAK inhibition (50).
Indeed, our data suggest that the capacity of CYT387 to inhibit
TBK1/IKBKE and JAK/STAT signaling, resulting in a particularly
potent anti-cytokine effect, may be advantageous over more
selective JAK1/2 inhibitors.
It is also clear that inhibition of any one pathway in genetically complex tumors typically results in feedback signaling
that limits the effectiveness of single-agent therapy. Indeed,
treatment of TNBC with MEK inhibitors leads to feedback activation of both receptor tyrosine kinase signaling and cytokines
(39). Conversely, CYT387 treatment modestly inhibited IKBKEdriven TNBC growth as a single agent but dramatically impaired
tumor growth and angiogenesis when combined with a MEK
inhibitor, revealing cooperativity of targeting these pathways
in vivo. Combination CYT387 and MEK inhibitor therapy was
also synergistic and resulted in tumor regressions in aggressive
Kras-p53 mutated murine lung cancer (30). Since cytokine signaling similarly limits the efficacy of PI3K/mTOR inhibitors in
breast cancer (51), further strategies for combination therapy
may be possible. Regardless, the particularly impressive synergy of CYT387 and GSK1120212 in an aggressive PDX model,
coupled with their advanced stages of clinical development, provides a strong rationale for pursuing clinical trials of this drug
combination in patients with TNBC.

Methods

Gene expression profiling. Analyses were performed using TCGA
data (2) and applied single-sample gene set enrichment analysis of
an IL-1 signature as described previously (26, 52). For details, see
the Supplemental Methods.
Cell culture. Breast cancer cell lines and 293T cells were cultured
using standard conditions. MDA-MB-468 cells were maintained in the
absence of CO2. MDA-MB-468 tumor spheroids were generated and
assayed in 3D culture as described previously (34). Detailed methods
are described in the Supplemental Methods.
Immunoblotting and ELISA. Immunoblotting was performed
according to standard protocols. Proteome Profiler and Cytokine Antibody Arrays were from R&D Systems. The Proteome Profiler Human
Cytokine Array Kit, Panel A (catalog no. ARY005), the Human CCL5/
Rantes Quantikine ELISA Kit (catalog no. DRN00B), and the Human
IL-6 ELISA Kit (catalog no. D6050) were also purchased from R&D
Systems. Details are provided in the Supplemental Methods.
ORF and shRNA expression. 293T cells were transiently transfected
with the indicated ORF expression constructs using FuGENE 6 (Promega). Using stable lentiviral transduction as previously described (52),
shRNA (shIKBKE-1, shIKBKE-2, shGFP) was successfully expressed
and its effects on the various breast cancer cell lines were analyzed using
stable lentiviral transduction as described previously (52). For detailed
methods and shRNA sequences see the Supplemental Methods.
Quantitative real-time PCR. mRNA was purified and qRT-PCR
was performed according to a standard protocol using the LightCycler
480 SYBR Green I Master (Roche). Data were normalized to 36B4. For
detailed methods and primer sequences see the Supplemental Methods.
Animal studies. Patient-derived human breast xenografts were
cultured as described previously (38, 53). pSTAT3 immunohistochemistry and pSTAT3/pERK immunoblotting were performed following
short-term treatment with CYT387. Tumor measurement was conducted in a blinded fashion over time. Details are provided in the Supplemental Methods.
Statistics. Statistical analysis was carried out using an IBM software package, SPSS V.22.0. Cell viability data are presented as mean
± SEM. Histology data are presented as mean ± SD of independent
results. Overall differences among the 4 groups (vehicle, GSK1120212,
CYT387, and CYT387 plus GSK112012) for all variables were determined by ANOVA. Differences between groups were examined using
the nonparametric independent-samples t test to determine the statistical significance. Two-sided P values of less than 0.05 were considered statistically significant.
Study approval. Human breast cancer tissues for the present
studies were obtained via core needle, skin punch biopsy, or surgical
resection following informed consent and processed in compliance
with NIH regulations and with approval from the Institutional Review
Board at Washington University in St. Louis. All mouse experiments
were conducted in accord with a Washington University Institutional
Animal Care and Use Committee–approved protocol.
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